Documents in this section are publicly available.
Before downloading these documents, please read our Online Code of Conduct.
This webpage is based on the chapters of the WMDA handbook.
General Organisation of a Registry
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
3.13 4.09 | Unrelated hematopoietic stem cell donors as research subjects Bone Marrow Transplantation (2011), 46: 10-13 | Discuss various implications of research participation of unrelated stem cell donors in research protocols. | Current (2017) |
| 10.13 | Donor and liability of donor registries, donor centres and collection centres-recommendations Bone Marrow Transplantation (2004), 33: 467-470 | The paper outlines the ethical aspects of liability of involved parties and the need for insurance coverage. The article has shortcoming with the respect to legal advices. | Under review (2017), for more details: |
| GRID | |||
2.11 2.11.1 | WMDA Quality Manual | ||
| Related donors | Family donor care management: principles and recommendations Bone Marrow Transplantation (2010) 45: 1269-1273 | This document hopes to encourage increased collaboration between those caring for related and unrelated donors, and build on the extensive work, which has already been undertaken in this field to homogenize care. | Current (2017) |
Recruitment of volunteer donors
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
3.22 3.22.2 | Guidance for assessing the medical suitability for adult volunteer donors | The guidance below reflects the consensus opinion provided by the WMDA donor medical suitability committee. The purpose of this guidance is to provide globally harmonised medical assessment criteria which simultaneously protect the interest of donors whilst ensuring the safety of cellular products across international boundaries. | Current (2017) |
| 3.02 | Bone Marrow Transplantation (2013) 48: 1480150 | Paper providing recommendations regarding qualifications and training of recruiters | |
| Key Performance Indicators for Registries | |||
| 3.03, 3.04, 3.09, 6.07, 6.07.1, 3.24, 10.11, 10.13 | Bone Marrow Transplantation (2010) 45: 832-838 | This paper is providing information about the donor care standards of the WMDA. The paper has been published in 2010, the wording of the WMDA Standards might have changed over time. | Current (2017) |
Donor search request
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
Recommendation on the training of staff performing patient donor search and HLA matching activities | |||
| Suggested procedures for international unrelated search | |||
| 7.01 | WMDA Guidelines for subsequent donations following initial BM or PBSCs Bone Marrow Transplantation (2011) 46: 1409-1412 | This guideline is intended to outline where subsequent donations would routinely be considered appropriate (from the donor's point-of-view), as well as the frequency and timing of such donations. | Under review, see https://share.wmda.info/x/8qWbEw for more information |
| 3.03, 3.06, 6.06 | Donor commitment and patient needs Bone Marrow Transplantation (2004) 33: 225-230 | This paper describes ethical issues related to the donation of hematopoietic stem cell products with respect to recruitment, evaluation, workup, and follow-up of unrelated donors. | Current (2017) |
Collection and transportation
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
8.05 | WMDA recommendation on the use of biosimilar filgrastims | Current (2018) | |
| 3.03 | Blood (2010) 117: 21-25 | This paper describes the reasons that the WMDA continues to believe that HSC donors should not be paid due to ethical concerns raised by remuneration, potential to damage the public will to act altruistically, the potential for coercion and exploitation of donors, increased risk to patients, harm to local transplantation programs and international stem cell exchange, and the possibility of benefiting some patients while disadvantaging others. | Current (2017) |
| 1.08 | Bone Marrow Transplantation (2018) | This paper describes the general requirements and recommendations for collaboration with the collection and apheresis centers and define critical procedures for the collection of the stem cell product, such as information session, medical assessment, product collection, quality controls, product handover for transportation, and donor follow-up. The specific guidelines are accompanied by detailed checklists and forms that can be found in Supplementary Information and may be used during an initial or follow-up on-site or paper-based audit. For more information you can visit: https://share.wmda.info/x/OAKQEQ | Current (2018) |
| Labeling |
Post-donation
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
Towards a global system | |||
Cord Blood Banking
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
Information technology and data management
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
2.11.2 | World marrow donor association crisis response, business continuity, and disaster recovery guidelines. | Current (2017) | |
Finance and administration
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
Publications in partnership with other professional societies
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
9.02 | Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). | Global consensus document to perform long-term follow up on donors till 10 years after donation. | Current (2017) |
Archived Publications
| WMDA Standard | Title and link to document | Explanation | Status |
|---|---|---|---|
3.04, 3.05, 3.06, 3.09, 3.10.1, 3.11, 3.11.1, 3.13, 3.15 | Bone Marrow Transplantation (2003) 31: 539-545 | This is a checklist to set up an informed consent at the various stages. The paper has been replaced by the WMDA Guidance to explain the WMDA Standards. The guidance can be found at: https://share.wmda.info/x/0wB7Cw | Out of date |
Bone Marrow Transplantation (2010), 45:819-824 | WMDA has developed online documentation to explain the accreditation process, which is available at WMDA Share under the pillar: 'Ensuring Quality' | Out of date | |
International exchange of cord blood units; the registry aspects Bone Marrow Transplantation (2010), 45: 825-831 | Replaced by chapter 6 of the WMDA handbook: a gift of life | Out of date | |
| 8.05 | Haematologica (2011): 96:942-943 | The aim of this paper is to review the basis of regulatory approval of the biosimilar G-CSF agents, including the available safety data, with reference to the indication for mobilization of PBSC in normal donors and to make recommendations based on these. The recommendation has been updated in 2017. | Out of date |
| Page Tree | ||||
|---|---|---|---|---|
|